- Home
- NRC vs ALDX Comparison
NRC vs ALDX Comparison
Compare NRC & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRC
- ALDX
- Stock Information
- Founded
- NRC 1981
- ALDX 2004
- Country
- NRC United States
- ALDX United States
- Employees
- NRC N/A
- ALDX N/A
- Industry
- NRC Biotechnology: Commercial Physical & Biological Resarch
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- NRC Health Care
- ALDX Health Care
- Exchange
- NRC Nasdaq
- ALDX Nasdaq
- Market Cap
- NRC 354.5M
- ALDX 326.6M
- IPO Year
- NRC N/A
- ALDX 2014
- Fundamental
- Price
- NRC $14.69
- ALDX $5.84
- Analyst Decision
- NRC
- ALDX Strong Buy
- Analyst Count
- NRC 0
- ALDX 2
- Target Price
- NRC N/A
- ALDX $9.50
- AVG Volume (30 Days)
- NRC 101.8K
- ALDX 825.9K
- Earning Date
- NRC 10-24-2025
- ALDX 08-07-2025
- Dividend Yield
- NRC 3.27%
- ALDX N/A
- EPS Growth
- NRC N/A
- ALDX N/A
- EPS
- NRC 0.77
- ALDX N/A
- Revenue
- NRC $140,314,000.00
- ALDX N/A
- Revenue This Year
- NRC N/A
- ALDX N/A
- Revenue Next Year
- NRC N/A
- ALDX $43.00
- P/E Ratio
- NRC $19.08
- ALDX N/A
- Revenue Growth
- NRC N/A
- ALDX N/A
- 52 Week Low
- NRC $9.76
- ALDX $1.14
- 52 Week High
- NRC $22.99
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- NRC 47.23
- ALDX 68.82
- Support Level
- NRC $14.45
- ALDX $5.74
- Resistance Level
- NRC $15.60
- ALDX $6.18
- Average True Range (ATR)
- NRC 0.66
- ALDX 0.25
- MACD
- NRC -0.03
- ALDX -0.00
- Stochastic Oscillator
- NRC 13.64
- ALDX 65.46
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.